AbbVie Inc. (abbv)
ABBV Estimates
Public analyst price targets and consensus snapshot for AbbVie Inc.. Deeper estimate history and models are available in Vest Terminal.
| Last price | $265.08 |
| Analyst mean target | $278.61 |
| Analyst high target | $328.00 |
| Analyst low target | $200.00 |
| Upside vs mean target | 5.1% |
| Consensus recommendation | Buy |
| Number of analysts | 28 |
| Forward P/E | 16.30 |
Start Free — open ABBV in Vest Terminal
Access live data, filings, ownership, and analysis for AbbVie Inc..
AbbVie Inc. FAQ
What does AbbVie Inc. (ABBV) do?
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruv…
What is ABBV's P/E ratio?
AbbVie Inc. has a trailing P/E of 75.09× based on publicly available market data.
Does ABBV pay a dividend?
Indicated dividend yield: 2.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is ABBV in?
AbbVie Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is ABBV's market capitalization?
Approximate market cap: $468.43B.
What are the main risks for ABBV?
Key risks include elevated valuation, among factors on this page.
What are the strengths of ABBV?
Potential positives include revenue growth of 10.2% year-over-year, earnings growth of 2.9% year-over-year.
Where can I get analyst estimates for ABBV?
Public analyst price targets and consensus for AbbVie Inc. are on the free /stocks/abbv/estimates page. Deeper estimate history and models are available in Vest Terminal.